West Pharmaceutical Services, Inc. WST SPX
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -5.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WST West Pharmaceutical Services, Inc. SPX | 322.81 | 43.10 | $22.81B | 0.27% | 16.28% | 19.13% | 2.12% | -5.55% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 443.50M | 469.70M | 456.10M | 470.60M | 491.50M | 527.20M | 548.00M | 580.20M | 670.70M | 723.60M | 706.50M | 720.00M | 771.30M | 686.90M | 716.60M | 753.80M | 747.40M | 695.40M | 702.10M | - | - | 698.00M | 766.50M | 804.60M | 805.00M | 844.90M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 466.10M | 492.60M | 510.30M | 501.10M | 548.50M |
| Gross Profit | 121.80M | 109.90M | 109.70M | 118.20M | 108.30M | 123.30M | 133.30M | 121.10M | 134.20M | 125.00M | 125.10M | 134.40M | 142.20M | 135.60M | 146.80M | 157.90M | 147.80M | 153.20M | 167.00M | 195.10M | 194.60M | 211.10M | 271.90M | 315.10M | 288.20M | 284.60M | 321.50M | 268.00M | 271.30M | 291.40M | 288.30M | 230.20M | 230.00M | - | - | 231.90M | 273.90M | 294.30M | 303.90M | 296.40M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 103.80M | 104.30M | 115.00M | 119.80M | - | 115.30M |
| Operating Income | 54.10M | 44.00M | 47.80M | 39.10M | -3.50M | 30.00M | 61.20M | 51.30M | 60.50M | 42.00M | 62.90M | 53.40M | 60.30M | 60.80M | 70.70M | 80.50M | 67.30M | - | 88.00M | 103.60M | 99.20M | - | 175.60M | 211.30M | 181.40M | 189.70M | 228.40M | 186.20M | 155.30M | 182.50M | 177.30M | 122.80M | 126.20M | - | - | 127.60M | 158.90M | 174.50M | 175.10M | 181.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 150.90M | 198.50M | 215.10M | 208.30M | 227.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 400.00K | 100.00K | 200.00K | -200.00K | 1.90M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 110.50M | 157.00M | 171.90M | 161.50M | 180.10M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.10M | 30.20M | 34.00M | 33.30M | 44.70M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.40M | 66.10M | 56.30M | 63.90M | 74.30M | 91.20M | 82.30M | 98.40M | 151.20M | 187.30M | 175.60M | 173.80M | 188.50M | 120.60M | 140.00M | 155.10M | 161.30M | 115.30M | 111.30M | - | - | 89.80M | 131.80M | 140.00M | 132.10M | 138.80M |
| Diluted EPS | 0.52 | 0.43 | 0.45 | 0.38 | 0.02 | 0.30 | 0.60 | 0.50 | 0.81 | 0.51 | 0.67 | 0.58 | 0.75 | 0.73 | 0.73 | 0.88 | 0.75 | 0.84 | 0.99 | 1.21 | 1.09 | 1.29 | 1.99 | 2.47 | 2.31 | 2.29 | 2.48 | 1.59 | 1.85 | 2.06 | 2.14 | 1.55 | 1.51 | - | - | 1.23 | 1.82 | 1.92 | 1.82 | 1.92 |
| R&D Expense | 9.90M | 9.60M | 7.50M | 8.10M | 8.50M | 9.40M | 8.80M | 9.00M | 10.30M | 10.00M | 9.10M | 9.60M | 10.80M | 10.10M | 9.80M | 9.60M | 9.30M | - | 10.70M | 10.80M | 12.50M | - | 12.20M | 13.80M | 13.10M | 14.60M | 14.40M | 13.60M | 17.10M | 16.50M | 16.40M | 17.60M | 17.50M | 15.50M | - | 16.30M | 19.10M | 17.10M | - | 15.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 1.72B | 1.84B | 2.15B | - | 2.89B | 2.95B | 2.89B | 3.07B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75B | 1.82B | 1.89B | 1.97B |
| Gross Profit | 302.60M | 303.60M | 318.10M | 339.30M | 387.70M | 434.70M | 447.80M | 455.80M | 501.40M | 512.90M | 545.40M | 605.70M | 767.80M | - | 1.14B | 1.13B | 998.50M | 1.10B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.40M | 421.80M | 407.60M | 467.90M |
| Operating Income | 124.10M | 97.50M | 90.70M | 109.60M | 135.10M | 162.40M | 182.00M | 128.60M | 195.20M | 225.80M | 240.30M | 296.60M | 406.90M | - | 760.80M | 707.40M | 590.90M | 636.10M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 808.40M | 844.30M | 743.90M | 772.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.90M | 9.00M | 3.00M | 500.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 679.90M | 698.00M | 585.50M | 600.90M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114.70M | 122.30M | 107.50M | 121.60M |
| Net Income | 86.00M | 72.60M | 65.30M | - | - | - | - | - | - | - | 206.90M | 241.70M | 346.20M | - | 585.90M | 593.40M | 492.70M | 493.70M |
| Diluted EPS | 2.50 | 2.12 | 1.89 | 1.08 | 1.15 | 1.57 | 1.75 | 1.30 | 1.91 | 1.99 | 2.74 | 3.21 | 4.57 | - | 7.73 | 7.88 | 6.69 | 6.79 |
| R&D Expense | 18.70M | 19.90M | 23.90M | 29.10M | 33.20M | 37.90M | 37.30M | 34.10M | 36.80M | 39.10M | 40.30M | 38.90M | 46.90M | 52.80M | 58.50M | 68.40M | 69.10M | 74.30M |
Compounded Sales Growth
| 5 Years: | 2.12% |
| 1 Year: | 21.00% |
Compounded Profit Growth
| 5 Years: | -5.55% |
| 1 Year: | 56.10% |
Stock Price Performance
| 1 Year: | +53.60% |
| 6 Months: | +15.14% |
| 3 Months: | +27.02% |
| 1 Month: | +9.29% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Sep 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.27B | 1.29B | - | 1.40B | 1.56B | 1.67B | 1.67B | 1.70B | 1.72B | 1.86B | 1.98B | 2.34B | 2.79B | - | 3.62B | 3.83B | 3.64B | 4.27B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.92B | 1.94B | 1.54B | 1.98B |
| Cash & Equivalents | 108.40M | 87.20M | 83.10M | 110.20M | 161.90M | 91.80M | 161.90M | 230.00M | 255.30M | 274.60M | 203.00M | 235.90M | 337.40M | 439.10M | 615.50M | - | 894.30M | 853.90M | 484.60M | 791.30M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 414.80M | 434.70M | 377.00M | 443.90M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 507.40M | 512.00M | 552.50M | 574.40M |
| Total Liabilities | - | - | 691.90M | 668.60M | - | 744.20M | 835.10M | 765.20M | 712.80M | 671.20M | 599.20M | 582.90M | 582.60M | 768.20M | 939.30M | - | 931.90M | 948.50M | 961.10M | 1.09B |
| Current Liabilities | - | - | 171.10M | 169.70M | - | 243.20M | 261.80M | 236.90M | 252.50M | 314.30M | 241.00M | 279.50M | 283.70M | 341.60M | 503.40M | - | 519.00M | 671.80M | 550.40M | 654.90M |
| Long Term Debt | - | - | 379.10M | 358.10M | - | 299.30M | 378.80M | 371.30M | 308.30M | 228.90M | 226.20M | 197.00M | 196.00M | 255.00M | 252.90M | - | 206.70M | 72.80M | 202.60M | 202.80M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 317.90M | 309.00M | 302.30M | 321.10M |
| Total Equity | - | - | - | - | - | - | - | - | - | - | - | 1.28B | 1.40B | 1.57B | 1.85B | - | 2.68B | 2.88B | 2.68B | 3.18B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 75.30M | 75.30M | 75.30M | 75.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 135.00M | 137.70M | 138.30M | 130.70M | 187.40M | 220.50M | 182.90M | 212.40M | 219.40M | 263.30M | 288.60M | 367.20M | 472.50M | - | 724.00M | 776.50M | 653.40M | 754.80M |
| Investing Cash Flow | -119.70M | -121.90M | -74.00M | -120.50M | -116.00M | -149.90M | -104.00M | -129.50M | -175.80M | -133.60M | -100.80M | -228.00M | -179.50M | - | -288.20M | -368.70M | -378.70M | -285.90M |
| Financing Cash Flow | -29.40M | -22.60M | -34.00M | -24.70M | -3.40M | -5.10M | -30.80M | -41.50M | -113.90M | -109.00M | -80.70M | -36.80M | -137.10M | - | -293.60M | -459.60M | -622.60M | -185.10M |
| Capital Expenditure | -138.60M | -104.90M | -71.10M | -95.40M | -131.30M | -151.90M | -111.90M | -131.60M | -170.20M | -130.80M | -104.70M | -126.40M | -174.40M | - | -284.60M | -362.00M | -377.00M | -285.90M |
| Free Cash Flow | -3.60M | 32.80M | 67.20M | 35.30M | 56.10M | 68.60M | 71.00M | 80.80M | 49.20M | 132.50M | 183.90M | 240.80M | 298.10M | - | 439.40M | 414.50M | 276.40M | 468.90M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.20M | -51.80M | -347.90M | 283.80M |
| Share Buybacks | 5.20M | 1.30M | 2.10M | 3.50M | 4.70M | - | 0 | 0 | 52.20M | 74.40M | 70.80M | 83.10M | 115.50M | 137.10M | 202.80M | 438.30M | 560.90M | 134.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | 31.8% | 32.9% | 35.8% | - | 39.4% | 38.3% | 34.5% | 35.9% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | 14.0% | 16.1% | 19.0% | - | 26.4% | 24.0% | 20.4% | 20.7% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | 12.0% | 13.1% | 16.1% | - | 20.3% | 20.1% | 17.0% | 16.1% |
| ROE % | - | - | - | - | - | - | - | - | - | - | 14.8% | 15.4% | 18.7% | - | 21.8% | 20.6% | 18.4% | 15.5% |
| ROCE % | - | 8.9% | 8.1% | 9.5% | 10.4% | 11.3% | 12.8% | 9.3% | 13.2% | 14.3% | 14.2% | 14.8% | 17.8% | - | 24.6% | 22.4% | 19.1% | 17.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.68% | 6.84M | $2.21B |
| 2 | Vanguard Capital Management LLC | 6.63% | 4.68M | $1.51B |
| 3 | Vanguard Portfolio Management LLC | 5.79% | 4.09M | $1.32B |
| 4 | State Street Corporation | 4.66% | 3.29M | $1.06B |
| 5 | Artisan Partners Limited Partnership | 3.76% | 2.66M | $857.99M |
| 6 | Bank Of New York Mellon Corporation | 3.49% | 2.47M | $796.00M |
| 7 | T. Rowe Price Investment Management, Inc. | 3.31% | 2.34M | $755.51M |
| 8 | Generation Investment Management LLP | 3.18% | 2.24M | $724.38M |
| 9 | Geode Capital Management, LLC | 2.71% | 1.91M | $617.36M |
| 10 | Morgan Stanley | 2.06% | 1.46M | $470.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WST